proposed, but until recently, have had limited uptake in the management of AF patients due to their complexity or being non-AF specific.
In 2010, the HAS-BLED score was proposed 6 which incorporated the more common bleeding risk factors in AF patients, and has since been recommended by guidelines.
Importantly, HAS-BLED draws attention to the reversible bleeding risk factors (e.g., Risk is not static, and particularly for bleeding, many risk factors can be modified.
Whilst stroke and bleeding risks track each other, it has been conclusively shown that the HAS-BLED score outperforms stroke scores such as CHADS 2 or CHA 2 DS 2 -VASc in predicting bleeding 7 . High risk of bleeding (e.g., HAS-BLED score ≥3) is not a reason to withhold OAC, instead such patients should be 'flagged-up' for more careful review and follow-up 8 . This is increasingly important in an era of electronic health records with 'electronic alerts' that identify patients requiring review.
HAS-BLED has also been shown to be predictive of serious bleeding in OAC (whether a VKA or non-VKA type), aspirin or no antithrombotic therapy [thus, applicable for the full spectrum of AF patients], and in AF and non-AF populations. HAS-BLED is also the only bleeding risk score shown to be predictive of ICH.
Other bleeding risk scores have been proposed for AF patients, such as the ATRIA and ORBIT scores, and more recently the ABC-bleeding score [9] [10] [11] . All these scores focus on identifying 'high risk' patients and some have added complexity by weighted scoring (ATRIA 9 ) or including biomarkers (ABC 11 ), or opted for even greater simplicity and supposed applicability to any OAC, whether VKA or NOAC (ORBIT 10 ).
Whilst some of the validation studies imply improved prediction (at least statistically) compared to other scores (including HAS-BLED), the crucial question for everyday clinical use is the simplicity and practical applicability of these new scores.
In 13 .
Addition of a biomarker to improve risk prediction is not a new concept 14 . More recent validation studies have used biomarkers in highly selected anticoagulated
clinical trial cohorts and have demonstrated modest, yet statistically significant predictive improvement over the risk scores based on clinical factors alone 15 . Also, many biomarkers have important inter-laboratory and inter-assay variability, as well as diurnal and temporal variation which need to be considered.
As shown recently, adding 'labile INR' (TTR < 65%) to the ORBIT, ATRIA and HEMORR 2 HAGES scores significantly improved their reclassification and discriminatory performances for major bleeding whilst on VKA, suggesting that these scores may perform sub-optimally in identifying serious bleeding risk in a patient on warfarin, unless they were re-calibrated taking labile INRs (or TTRs) into consideration 16, 17 . In contrast, HAS-BLED categorised adjudicated major bleeding events in low-risk and high-risk patients appropriately, whilst ORBIT and ATRIA classified most major bleeds into their 'low-risk' categories 16 .
Another clear misuse of bleeding risk scores is as an excuse to withhold OAC. Focks et al 12 clearly show a favorable trade-off for OAC in this elderly cohort, consistent with the broad literature showing that the NCB is even greater among the elderly, since in most cases, the magnitude of gain from stroke prevention far outweighs the smaller risk of serious bleeding even at high HAS-BLED scores 18 .
Bleeding risk scores should thus be applied appropriately and not misused [FIGURE] .
The continued preoccupation with trying to improve prediction of 'high risk' patients with ever more complex scores and (often multiple biomarkers) with only marginal improvement in predictive performance, at the cost of simplicity and practically, would seem counterintuitive for everyday clinical management. Risk is also a continuum, and patients often do not fall neatly into 3 artificially defined (i.e. low, moderate and high) risk categories. Risk is also not static 'one-off' assessment, and since AF patients are often elderly with multiple comorbidities, risk assessment has to be dynamic with regular review and reassessment -with particular attention to reversible risk factors, whether for bleeding or stroke.
The continued misuse of these scores will ultimately be to the detriment of AF patient management, and greater awareness and understanding of appropriate practical use is needed. Ultimately, patients place greater value on stroke prevention, and even to avoid one stroke (regarded by some as a fate worse than death) patients may be prepared to sustain 4 major bleeds 19, 20 . Surely we can do better.
FIGURE 1
Appropriate use of bleeding risk assessment in patients with atrial fibrillation
